BCAA (2:1:1) — The Muscle Protein Synthesis Activators

Branched-chain amino acids (BCAAs)—leucine, isoleucine, and valine—are essential amino acids that bypass hepatic metabolism and are oxidized directly in skeletal muscle. Leucine is the primary driver of muscle protein synthesis via direct activation of the mechanistic target of rapamycin complex 1 (mTORC1). Isoleucine promotes glucose uptake into cells, while valine helps prevent excess tryptophan transport into the brain, reducing central fatigue. In the context of aging, BCAA supplementation aims to overcome anabolic resistance, a state where older muscle requires higher amino acid thresholds to stimulate protein synthesis.

Human trials primarily focus on sports performance, muscle recovery, and sarcopenia in older adults, often in combination with resistance training or other nutrients (e.g., vitamin D). Evidence for isolated BCAA supplementation extending human lifespan or healthspan independent of exercise or correcting malnutrition is lacking. No published human longevity trials. Animal/in-vitro evidence only.

5–10 g per day, typically consumed before, during, or after exercise. The 2:1:1 ratio refers to leucine, isoleucine, and valine, respectively. Often taken as a powder mixed with water. Unestablished as a standalone longevity intervention in humans without exercise.

Generally recognized as safe at standard doses. High doses may cause gastrointestinal distress (nausea, diarrhea). Chronically elevated BCAA levels in the blood are associated with insulin resistance and type 2 diabetes, though it is unclear if dietary BCAAs cause this or if it reflects impaired BCAA catabolism. Contraindicated in individuals with maple syrup urine disease (MSUD) or amyotrophic lateral sclerosis (ALS).

Key Papers